ADEF
LEGN icon

ABS Direct Equity Fund’s Legend Biotech LEGN Stock Holding History

ABS Direct Equity Fund’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47,200
Closed -$1.03M – 114
2025
Q4 		$1.03M Buy
47,200
+14,100
+43% +$404K 1.22% 28
2025
Q3 		$1.08M Hold
33,100
– – 1.54% 24
2025
Q2 		$1.17M Hold
33,100
– – 1.87% 21
2025
Q1 		$1.12M Buy
+33,100
New +$1.19M 1.5% 26

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ABS Direct Equity Fund's LEGN Position: Q1 2026 in Review

ABS Direct Equity Fund sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 47,200 shares — an estimated $1.03M sold.

ABS Direct Equity Fund first reported a position in LEGN in Q1 2025 and held it in 4 quarters. The position peaked at $1.17M in Q2 2025. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • ABS Direct Equity Fund reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
  • ABS Direct Equity Fund sold 47,200 Legend Biotech shares in Q1 2026, an estimated $1.03M.
  • ABS Direct Equity Fund first reported a position in Legend Biotech in Q1 2025 and held it in 4 quarters.
  • ABS Direct Equity Fund's Legend Biotech position peaked at $1.17M in Q2 2025.
  • 190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on ABS Direct Equity Fund's 13F filing for Q1 2026, filed 15 May 2026.